TY - JOUR
T1 - High prevalence of peripheral neuropathy in multiple myeloma patients and the impact of vitamin D levels, a cross-sectional study
AU - Oortgiesen, B E
AU - Kroes, J A
AU - Scholtens, P
AU - Hoogland, J
AU - Dannenberg-de Keijzer, P
AU - Siemes, C
AU - Jansman, F G A
AU - Kibbelaar, R E
AU - Veeger, N J G M
AU - Hoogendoorn, M
AU - van Roon, E N
N1 - Funding Information:
The authors would like to acknowledge the patients who participated in the study, and thank the HemoBase Population Registry Consortium for its contribution. HemoBase Population Registry Consortium: Antonius hematology, Sneek: Gerrit Jan Veldhuis, Gerhard Woolthuis, Leonie van der Burg; Tjongerschans hematology, Heerenveen: Bas van Rees; Medisch Centrum Leeuwarden hematology: Mels Hoogendoorn, Bas Franken, Esther de Waal, Rozemarijn van Rijn; Medisch Centrum Leeuwarden klinische farmacologie: Eric van Roon, Berdien Oortgiesen; Medisch Centrum Leeuwarden Science bureau: Nic Veeger; Nij Smellinghe hematology, Drachten: Sjoerd Hovenga, Frank Schipper, Harmen van Kamp; Nij Smellinghe clinical chemistry: Adrian Kruit; Certe Medical Diagnostics & Advice: Huib Storm, Harry de Wit, Willeke Ferket-Franken; Radiotherapy Institute Friesland: Wilma Smit, Renske Vlasman; Pathology Friesland: Robby Kibbelaar, Roy Jurhill, Sophie Dijkhuizen; UMCG Genetics: Eva van den Berg-de Ruiter.
Publisher Copyright:
© 2021, The Author(s).
PY - 2022/1
Y1 - 2022/1
N2 - Purpose: Peripheral neuropathy (PN) is common in patients with multiple myeloma (MM). We hypothesized that the relationship between hypovitaminosis D and PN described in diabetes mellitus patients may also be present in MM patients. Methods: To study this potential association, we assessed the incidence of hypovitaminosis D (vitamin D < 75 nmol/L [= 30 ng/mL]) in smouldering and active MM patients in two Dutch hospitals. Furthermore, a validated questionnaire was used to distinguish different PN grades. Results: Of the 120 patients included between January 2017 and August 2018, 84% had an inadequate vitamin D level (median vitamin D level 49.5 nmol/L [IQR 34–65 nmol/L]; mean age: 68 years [SD ± 7.7]; males: 58%). PN was reported by 69% of patients (n = 83); however, of these 83 patients, PN was not documented in the medical records of 52%. An association was found between lower vitamin D levels and higher incidence of PN in the total population (P = 0.035), and in the active MM patients (P = 0.016). Conclusion: This multi-centre cohort study showed that PN and hypovitaminosis D are common in MM patients, and addressing low vitamin D levels in the treatment of MM patients might be beneficial in reducing the risk of PN. More attention for PN is warranted, as PN is underreported by clinicians. Further research is needed to fully understand the implications of vitamin D in the development of PN in patients with MM. Clinical trial registration: Netherland Trial Register NL5835, date of registration July 28, 2016.
AB - Purpose: Peripheral neuropathy (PN) is common in patients with multiple myeloma (MM). We hypothesized that the relationship between hypovitaminosis D and PN described in diabetes mellitus patients may also be present in MM patients. Methods: To study this potential association, we assessed the incidence of hypovitaminosis D (vitamin D < 75 nmol/L [= 30 ng/mL]) in smouldering and active MM patients in two Dutch hospitals. Furthermore, a validated questionnaire was used to distinguish different PN grades. Results: Of the 120 patients included between January 2017 and August 2018, 84% had an inadequate vitamin D level (median vitamin D level 49.5 nmol/L [IQR 34–65 nmol/L]; mean age: 68 years [SD ± 7.7]; males: 58%). PN was reported by 69% of patients (n = 83); however, of these 83 patients, PN was not documented in the medical records of 52%. An association was found between lower vitamin D levels and higher incidence of PN in the total population (P = 0.035), and in the active MM patients (P = 0.016). Conclusion: This multi-centre cohort study showed that PN and hypovitaminosis D are common in MM patients, and addressing low vitamin D levels in the treatment of MM patients might be beneficial in reducing the risk of PN. More attention for PN is warranted, as PN is underreported by clinicians. Further research is needed to fully understand the implications of vitamin D in the development of PN in patients with MM. Clinical trial registration: Netherland Trial Register NL5835, date of registration July 28, 2016.
U2 - 10.1007/s00520-021-06414-3
DO - 10.1007/s00520-021-06414-3
M3 - Article
C2 - 34273034
SN - 0941-4355
VL - 30
SP - 271
EP - 278
JO - Supportive Care in Cancer
JF - Supportive Care in Cancer
IS - 1
ER -